Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
    Most visited pages

        MEDI-SCIENCE R&D FRAMEWORK (I2I)

        Signature(s)

        Amount
        € 227,000,000
        Countries
        Sector(s)
        Germany : € 227,000,000
        Industry : € 113,500,000
        Services : € 113,500,000
        Signature date(s)
        13/07/2005 : € 20,500,000
        13/07/2005 : € 20,500,000
        13/07/2005 : € 45,000,000
        13/07/2005 : € 45,000,000
        15/09/2005 : € 48,000,000
        15/09/2005 : € 48,000,000

        Summary sheet

        Release date
        16 June 2004
        Status
        Reference
        Signed | 13/07/2005
        20030508
        Project name
        Promoter - financial intermediary
        Medi-Science R & D Framework (i2i)
        Fresenius – The Health Care Group.
        Proposed EIB finance (Approximate amount)
        Total cost (Approximate amount)
        EUR 232m.
        Up to EUR 330m.
        Location
        Sector(s)
        Description
        Objectives

        The project concerns the promoter’s Research and Development expenditures in medical care and biotechnology (antibodies and cell therapy) and upgrading of existing manufacturing facilities for dialysis and products.

        The research activities aim at the innovation of high-quality products and new therapy approaches in line with the Bank’s Innovation 2010 Initiative. The promoter’s main production facilities in dialysis technology are located in Objective 2 areas for allocations from the EU Structural Fund. The project will result in creation of some new jobs while safeguarding existing employment.

        Environmental aspects
        Procurement

        Compliance with EU environmental directives and national laws shall be ensured.

        Procurement regulations do not apply to this private industry project. The promoter carries out competitive enquiries among potential suppliers for goods and services, as is usual in the industry.

        Comments

        Fabrication of medical equipment and pharmaceuticals.

        Disclaimer

        Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
        They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

        General enquiries and comments

        The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
        Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
        Alternatively, the EIB can be contacted through its external offices.
        Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

        Media enquiries

        Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

        Complaints mechanism

        Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

        Zero tolerance against fraud and corruption

        The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

        Related publications